News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
762,646 Results
Type
Article (59349)
Company Profile (507)
Press Release (702790)
Section
Business (220201)
Career Advice (2872)
Deals (37731)
Drug Delivery (115)
Drug Development (87299)
Employer Resources (180)
FDA (17337)
Job Trends (16288)
News (373787)
Policy (36445)
Tag
Academia (2928)
Alliances (53733)
Alzheimer's disease (1352)
Approvals (17251)
Artificial intelligence (167)
Bankruptcy (384)
Best Places to Work (12350)
Biotechnology (369)
Breast cancer (197)
Cancer (1411)
Cardiovascular disease (120)
Career advice (2409)
Cell therapy (299)
Clinical research (69357)
Collaboration (479)
Compensation (249)
COVID-19 (2781)
C-suite (118)
Data (1396)
Diabetes (175)
Diagnostics (6577)
Drug pricing (104)
Earnings (88921)
Employer resources (157)
Events (120347)
Executive appointments (383)
FDA (17996)
Funding (435)
Gene therapy (217)
GLP-1 (691)
Government (4833)
Healthcare (20381)
Infectious disease (2876)
Inflammatory bowel disease (124)
Interviews (552)
IPO (17093)
Job creations (4369)
Job search strategy (1998)
Layoffs (476)
Legal (8979)
Lung cancer (205)
Manufacturing (212)
Medical device (14311)
Medtech (14316)
Mergers & acquisitions (20744)
Metabolic disorders (490)
Neuroscience (1696)
NextGen Class of 2024 (7357)
Non-profit (4943)
Northern California (1678)
Obesity (284)
Opinion (231)
Patents (123)
People (62151)
Phase I (21544)
Phase II (30398)
Phase III (22709)
Pipeline (515)
Postmarket research (3028)
Preclinical (9363)
Radiopharmaceuticals (256)
Rare diseases (277)
Real estate (6639)
Regulatory (24143)
Research institute (2596)
Resumes & cover letters (455)
Southern California (1462)
Startups (4007)
United States (15572)
Vaccines (642)
Weight loss (220)
Date
Last 7 days (709)
Last 30 days (2475)
Last 365 days (37330)
2024 (36479)
2023 (42159)
2022 (53499)
2021 (58218)
2020 (57076)
2019 (50443)
2018 (38274)
2017 (35317)
2016 (35493)
2015 (41546)
2014 (35734)
2013 (31242)
2012 (33335)
2011 (33803)
2010 (32508)
Location
Africa (951)
Arizona (216)
Asia (43562)
Australia (7813)
California (3843)
Canada (1429)
China (302)
Colorado (175)
Connecticut (188)
Europe (97323)
Florida (522)
Georgia (139)
Illinois (426)
Indiana (227)
Maryland (657)
Massachusetts (3064)
Michigan (178)
Minnesota (302)
New Jersey (1107)
New York (1082)
North Carolina (835)
Northern California (1678)
Ohio (149)
Pennsylvania (920)
South America (1341)
Southern California (1462)
Texas (557)
Utah (110)
Washington State (413)
762,646 Results for "hemaflo therapeutics inc formerly known as drp medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
October 23, 2024
·
5 min read
Genetown
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR) announced today the publication of its clinical validation of a novel drug-specific DRP®-companion diagnostic (CDx) for dovitinib in the peer-reviewed journal PLOS ONE.
August 30, 2023
·
8 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Press Releases
StimCell Energetics Inc. (Formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding
November 4, 2024
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Deals
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
GT Medical Technologies, Inc. (GT MedTech) announces the successful acquisition of Cesium-131 and related assets from Isoray Medical, a subsidiary of Perspective Therapeutics, Inc.
April 15, 2024
·
5 min read
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Genetown
First Prospective Clinical Validation of Allarity’s DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
Allarity Therapeutics, Inc. announced the results of a prospective Phase 2 clinical study of the Company’s proprietary DRP® technology that will be presented in a poster at the 2023 American Society of Clinical Oncology Annual Meeting on June 3, 2023.
May 30, 2023
·
8 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
1 of 76,265
Next
